Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1361-1366

  Mullen, Craig A ^a   Petropoulos, Demetrios ^a   Lowe, Robert M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; INTERLEUKIN 6; RECOMBINANT VACCINE; TUMOR VACCINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; DRUG EFFECT; DRUG EFFICACY; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC TRANSDUCTION; IMMUNOGENICITY; IMMUNOMODULATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOCARCINOMA; ANIMALS; CARCINOGENS; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; CYTOSINE DEAMINASE; DIMETHYLHYDRAZINES; DISEASE PROGRESSION; FEMALE; FIBROSARCOMA; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; LUNG NEOPLASMS; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; NUCLEOSIDE DEAMINASES; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0029878461     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Mullen, C A., and Blaese, R. M. Gene therapy of cancer In: H. M. Pinedo, D L. Longo, and B. A. Chabner (eds.), Cancer Chemotherapy and Biological Response Modifiers Annual 15, pp. 176-189. New York. Elsevier Science Publishing Co., 1994.
2. Mullen, C. A The use of suicide vectors for the gene therapy of cancer Pharmacol. & Ther., 63: 199-207, 1994.
3. Consalva, M., Mullen, C. A , Modesti, A., Musiani, P., Allione, A., Cavallo, F., Giovarelli, M., and Forni, G. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J. Immunol., 154: 5302-5312, 1995
4. Mullen, C. A., Coale, M. M., Lowe, R., and Blaese, R. M Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor Cancer Res , 54: 1503-1506, 1994.
5. Tapscott, S. J., Miller, A. D., Olson, J. M., Berger, M. S., Groudine, M., and Spence, A. M. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection Proc. Natl. Acad. Sci. USA, 91: 8185-8189, 1994.
6. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component Cancer Res., 54. 6228-6234, 1994.
7. Barba, D , Hardin, J., Sadelain, M , and Gage, F. H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA, 91: 4348-4352, 1994.
8. Fearon, E. R , Itaya, T., Hunt, B , Vogelstein, B., and Frost, P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res., 48. 2975-2980, 1988.
9. Plautz, G. E., Yang, Z. Y , Wu, B. Y. Gao, X., Huang, L., and Nabel, G. J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl. Acad. Sci. USA, 90. 4645-4649, 1993.
10. Gansbacher, B., Rosenthal, F. M., and Zier, K. Retroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest , 11: 345-354, 1993.
11. Mullen, C. A., Coale, M. M., Levy, A. T., Stetler-Stevenson, W. G., Liotta, L. A., Brandt, S., and Blaese, R. M. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res., 52. 6020-6024, 1992.
12. Restifo, N. P., Esquivel, F., Asher, A L , Stotter, H., Barth, R. J., Bennick, J. R., Mule, J. J., Yewdell, J. W., and Rosenberg, S. A. Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J. Immunol., 147: 1453-1459, 1991
13. Cornetta, K., and Anderson, W. F Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy J. Virol. Methods, 23: 187-194, 1989.
14. Mullen, C. A , Kilstrup, M , and Blaese, R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci USA, 89: 33-37, 1992.
15. Morgenstern, J. P., and Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18: 3587-3596, 1990.
16. Urban, J L., Burton, R. C., Holland, J. M., Kripke, M. L., and Schreiber, H Mechanisms of syngeneic tumor rejection Susceptibility of host-selected progressor variants to various immunological effector cells. J. Exp. Med., 155: 557-573, 1982
17. Bi, W. L , Parysek, L M., Warnick, R., and Stambrook, P. J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther., 4: 725-731, 1993.
18. Freeman, S M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D S , Moolten, F. L., and Abraham, G N. The "bystander effect", tumor regression when a fraction of the tumor mass is genetically modified Cancer Res , 53: 5274-5283, 1993.
19. Perry, G. A., Jackson, J. D., and Talmadge, J. E. Effects of a multidrug chemotherapy regimen on the thymus. Thymus, 23: 39-51, 1994.
20. Talmadge, J. E., Jackson, J. D , Borgeson, C. D., and Perry, G. A. Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy. Cancer Immunol. Immunother., 39: 59-67, 1994.
21. Keene, J., and Forman, J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp. Med , 155: 768-782, 1982.